Zobrazeno 1 - 2
of 2
pro vyhledávání: '"Marie Duboys de la barre"'
Autor:
Delphine Loirat, Marie Duboys de la barre, Cristian Villanueva, Audrey Mailliez, Nicolas Isambert, Lionel Moreau, Emmanuelle Jacquet, Dominique Spaëth, Anne Creisson, Christelle Jouannaud, Eric Legouffe, Miguel delbado, Laura Deiana, Pauline Soibinet, Ioana Hrab, Thomas grellety, Nadine Dohollou, Raffaele Longo, Jean-Christophe Thery, Jean-david Fumet, Sellam Zineb, Pascal Pujol, thibault DE LA MOTTE ROUGE
Publikováno v:
Cancer Research. 83:P4-01
Background: Talazoparib (TALA) is a highly potent, dual-mechanism PARP inhibitor that has demonstrated clinical benefit in EMBRACA Phase III trial for patients with germline BRCA1/2 (BRCA1/2)-mutated locally advanced or metastatic HER2- breast cancer
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::fc1c8fe6852a68e7710080a52b1ec431
https://doi.org/10.1158/1538-7445.sabcs22-p4-01-04
https://doi.org/10.1158/1538-7445.sabcs22-p4-01-04
Autor:
Delphine Loirat, Marie Duboys de la barre, Jean-Christophe Thery, Ioana Hrab, Christelle Jouannaud, Jean-Loup Mouysset, Laura Salabert, Pauline Soibinet, Audrey Mailliez, Romain Valery, Anne Creisson, Cristian Villanueva, Nadine Dohollou, Jean-david Fumet, Thomas grellety, Nathalie Perez-staub, Emma Lachaier, Aurore Iltis-roux, Miguel delbado, Abeer Najem, Romuald Le Scodan, Elsa Curtit, kais aldabbagh, Pascal Pujol, thibault DE LA MOTTE ROUGE
Publikováno v:
Cancer Research. 83:P4-01
Background: Talazoparib (TALA) is a highly potent, dual-mechanism PARP inhibitor that has demonstrated clinical benefit in EMBRACA Phase III trial for patients with germline BRCA1/2 mutated locally advanced or metastatic HER2- breast cancer. Objectiv
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::9a596f8224ee2027f488b49261ea03bf
https://doi.org/10.1158/1538-7445.sabcs22-p4-01-20
https://doi.org/10.1158/1538-7445.sabcs22-p4-01-20